Navigation Links
Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
Date:1/19/2011

CAMBRIDGE, Mass., Jan. 19, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis (the spread of cancer cells to secondary locations). A cornerstone of Pervasis' oncology program, the company has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT) for all discovery and development activities associated with cellular implants for cancer diagnosis, prognosis and treatment. In addition, supportive evidence from multiple preclinical studies demonstrates the powerful anti-angiogenic, anti-proliferative and anti-inflammatory properties of this endothelial cell-based approach in the presence of various solid tumor cancers, such as brain, lung, breast and prostate.

Pervasis, a clinical stage company based in Cambridge, Mass., is focused on developing breakthrough cell-based therapies that harness the healing power of the endothelium, the thin layer of cells that lines the interior surface of every blood vessel in the body. The company's other areas of clinical investigation include improving outcomes following common vascular surgical and interventional procedures, such as hemodialysis access, angioplasties, stents and peripheral and coronary bypass grafts -- the failures of which result in serious complications and a significant increase in medical costs.

"We are very excited to expand our focus to include the critical area of oncology," stated Frederic Chereau, president and chief executive officer of Pervasis. "We already have amassed a significant amount of data demonstrating the safety and efficacy of utilizing our novel cell-based approach to improve outcom
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
3. PTC Therapeutics President and CEO Elected AAAS Fellow
4. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
5. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
6. Echo Therapeutics to Present at the OneMedForum 2011 Conference
7. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
8. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
9. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.C. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Medical Equipment, Inc. for the third straight year, ... Inc. 500|5000, an exclusive ranking of the nation,s ... comprehensive look at the most important segment of ... Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and ...
(Date:8/21/2014)... 21, 2014  Seventy-one percent of Americans believe the abuse ... serious public health and safety issue in the ... released today by Repass & Partners, a Cincinnati ... understand the severity of the prescription medication abuse problem and ... very serious health situation facing our country," Rex Repass ...
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
... (Nasdaq: MYL ) today announced that Mylan ... a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor ... connection with Mylan Specialty,s Abbreviated New Drug Application (ANDA) ... 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex® 2
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... to be filed in U.S. courts on behalf ... due to their use of prescription low testosterone ... documents, a new claim was filed against Pfizer ... who allegedly suffered life-threatening heart issues due to ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... Ultrasound and Management Practice Software to Support Advanced Diagnoses ... ... Oct. 21 South Carolina Veterinary,Specialists (SCVS), a leading regional ... Digital Practice(R) at its,new state-of-the-art facility in Columbia. The Eklin ...
... EXTON, Pa., Oct. 21 Isolagen(TM), Inc. (Amex:,ILE) ... in the Phase,II/III Study IT-A-008 investigating Isolagen Therapy(TM) ... scars. Further, approximately half of all,of the study ... the acne study will conclude in the first ...
... Is Safe And Active in Recurrent Ovarian Cancer; ... Oct. 21 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... results of the company,s proprietary polymer DACH,platinum prodrug, ... this week at a major international oncology conference ...
... reserve compensates for brain damage, study says , , TUESDAY, ... of education and a mentally demanding job may help ... according to an Italian study. , It included 242 ... 144 with no memory problems. People with mild cognitive ...
... players reach the base faster that way , , TUESDAY, Oct. ... slide head first or feet first during Wednesday,s first game ... a physicist instead of a coach. , The effectiveness of ... and factors like a baseball player,s center of gravity, explained ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
Cached Medicine News:Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 2Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 3Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 2Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 3Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 3Health News:Job, Education May Buffer Against Dementia 2Health News:Head-First Slide a Heads-Up Play 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3
Calibration plasmas for Assays of Low Molecular Weight Heparins (LMWH)using the Anti-Xa method on STA© Analyzers....
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: